Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer
Renske A. de Jong, Ninke Leffers, H. Marike Boezen, et al.
Gynecologic Oncology (2009) Vol. 114, Iss. 1, pp. 105-110
Closed Access | Times Cited: 205

Showing 1-25 of 205 citing articles:

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
Marloes J.M. Gooden, Geertruida H. de Bock, Ninke Leffers, et al.
British Journal of Cancer (2011) Vol. 105, Iss. 1, pp. 93-103
Open Access | Times Cited: 1189
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Advances in Anatomic Pathology (2017) Vol. 24, Iss. 6, pp. 311-335
Open Access | Times Cited: 671
The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature
Ronald J. deLeeuw, Sara E. Kost, Juzer Kakal, et al.
Clinical Cancer Research (2012) Vol. 18, Iss. 11, pp. 3022-3029
Open Access | Times Cited: 425
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity
Caroline Jochéms, Jeffrey Schlom
Experimental Biology and Medicine (2011) Vol. 236, Iss. 5, pp. 567-579
Open Access | Times Cited: 331
The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis
Yan Mao, Qing Qu, Yuzi Zhang, et al.
PLoS ONE (2014) Vol. 9, Iss. 12, pp. e115103-e115103
Open Access | Times Cited: 206
Molecular approaches for classifying endometrial carcinoma
Josep M. Piulats, Esther Guerra, Marta Gil-Martín, et al.
Gynecologic Oncology (2016) Vol. 145, Iss. 1, pp. 200-207
Closed Access | Times Cited: 175
The multifaceted role of autophagy in cancer and the microenvironment
Hendrik Folkerts, Susan Hilgendorf, Edo Vellenga, et al.
Medicinal Research Reviews (2018) Vol. 39, Iss. 2, pp. 517-560
Open Access | Times Cited: 172
Therapeutic targeting of regulatory T cells in cancer
Feng Shan, Ashwin Somasundaram, Tullia C. Bruno, et al.
Trends in cancer (2022) Vol. 8, Iss. 11, pp. 944-961
Open Access | Times Cited: 119
Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Mohammad Kazemi, Maryam Sadri, Alireza Najafi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 89
A Review of the Application of Inflammatory Biomarkers in Epidemiologic Cancer Research
Darren R. Brenner, Dominique Scherer, Kenneth Muir, et al.
Cancer Epidemiology Biomarkers & Prevention (2014) Vol. 23, Iss. 9, pp. 1729-1751
Open Access | Times Cited: 155
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives
Jole Ventriglia, Immacolata Paciolla, Carmela Pisano, et al.
Cancer Treatment Reviews (2017) Vol. 59, pp. 109-116
Closed Access | Times Cited: 144
PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors
Emily A. Sloan, Kari L. Ring, Brian C. Willis, et al.
The American Journal of Surgical Pathology (2016) Vol. 41, Iss. 3, pp. 326-333
Closed Access | Times Cited: 127
CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma
Hagma H. Workel, Fenne L. Komdeur, Maartje C.A. Wouters, et al.
European Journal of Cancer (2016) Vol. 60, pp. 1-11
Open Access | Times Cited: 126
A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer
Angela K. Green, Jacqueline Feinberg, Vicky Makker
American Society of Clinical Oncology Educational Book (2020), Iss. 40, pp. 238-244
Open Access | Times Cited: 126
Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma
Aline Talhouk, Heather Derocher, Pascal Schmidt, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 8, pp. 2537-2548
Open Access | Times Cited: 122
Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Piera Gargiulo, Chiara Della Pepa, Simona Berardi, et al.
Cancer Treatment Reviews (2016) Vol. 48, pp. 61-68
Closed Access | Times Cited: 114
Long non-coding RNA NIFK-AS1 inhibits M2 polarization of macrophages in endometrial cancer through targeting miR-146a
Yunxiao Zhou, Wei Zhao, Liwei Mao, et al.
The International Journal of Biochemistry & Cell Biology (2018) Vol. 104, pp. 25-33
Closed Access | Times Cited: 107
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression.
Graeme J. Koelwyn, Erik Wennerberg, Sandra Demaria, et al.
PubMed (2015) Vol. 29, Iss. 12, pp. 908-20, 922
Closed Access | Times Cited: 106
Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
Gloria Mittica, Eleonora Ghisoni, Gaia Giannone, et al.
Oncotarget (2017) Vol. 8, Iss. 52, pp. 90532-90544
Open Access | Times Cited: 99
New therapies for advanced, recurrent, and metastatic endometrial cancers
Vicky Makker, Angela K. Green, Robert M. Wenham, et al.
Gynecologic Oncology Research and Practice (2017) Vol. 4, Iss. 1
Open Access | Times Cited: 97
The immune system in the normal endometrium and implications for endometrial cancer development
Anke Vanderstraeten, Sandra Tuyaerts, Frédéric Amant
Journal of Reproductive Immunology (2015) Vol. 109, pp. 7-16
Closed Access | Times Cited: 96
Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma
Kirsten Kübler, Tiyasha H. Ayub, Sarah K. Weber, et al.
Gynecologic Oncology (2014) Vol. 135, Iss. 2, pp. 176-183
Closed Access | Times Cited: 95
Immunotherapy in endometrial cancer: rationale, practice and perspectives
Wenyu Cao, Xinyue Ma, Jean Victoria Fischer, et al.
Biomarker Research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 80
Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies
Ye Yang, Su Fang Wu, Wei Bao
International Journal of Gynecology & Obstetrics (2023) Vol. 164, Iss. 2, pp. 436-459
Open Access | Times Cited: 38
The prognostic impact of anti-cancer immune response: a novel classification of cancer patients
Gabriela Bindea, Bernhard Mlecnik, Wolf H. Fridman, et al.
Seminars in Immunopathology (2011) Vol. 33, Iss. 4, pp. 335-340
Open Access | Times Cited: 107
Page 1 - Next Page

Scroll to top